MCL1 and chronic myelogenous leukemia, BCR-ABL1 positive: TKI resistance was also described to be associated with a STAT1-dependent upregulation of BCL6 in CD34+ CML stem cells and a combination of TKIs with inhibitors of BCL6 (FX1) or MCL1 (A-1210477) is sufficient to overcome this resistance in LSCs [20].